Clinical Trial Search

Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume

Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV

Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability

Primary: Progression-free Survival at 6 Months — 23 Percentage of participants

Primary: Number of Participants With the Presence of Drug in the Tumor Tissue — 2 Participants

Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants

Primary: Extent of Tumor Resection — 40; 7; 7; 4 participants

Primary: 6-month Progression-free Survival (PFS), Defined as a Patient Being Alive and Progression-free 183 Days After the Date of Registration. — 33.35; 33.3; 25 percentage of…

Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants

Primary: Fraction of Time That Brain Oxygen Levels Are Below the Critical Threshold of 20 mm Hg . — 0.15; 0.44 Proportion

Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…

Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants

Primary: Endocrine Dysfunction — 14.5; 20.2 percentage of participants

Primary: Change in AUC0-18 of the Temozolomide Concentration (AUC-T) in Brain Interstitium Before and After Regadenoson Infusion — 19.1; 18.0 percentage of AUC

Primary: Change in PBR Uptake (Changes in PBR Uptake by PET) — 1.301; 1.1219 percent change from baseline

Primary: Contrast-to-noise Ratio (CNR) — 60.6; 58.4 contrast-to-noise ratio

Primary: To Measure the Reproducibility of qDCE-MRI Measurement of Glioblastoma. — 5 %COV

Primary: Number of Participants Experiencing the Incidence of Grade One or Higher Adverse Events — 12 participants

Primary: Progression-Free Survival — 7.71 weeks

Primary: Hemostasis at the Target Bleeding Site (TBS) at 6 Minutes Following Treatment Application. Hemostasis is Defined as no Detectable Bleeding at the TBS. — 99.2; 100 % of…

Primary: Progression of Disease — 14 Participants

Primary: Number of Participants Who Received PET/CT and MRI Perfusion Studies — 53; 95 Participants

Primary: Local Tumor Control — 0.966; 0.959; 1.000; 1.000 Proportion of patients

Primary: Number of Patients With a Decrease in Median Tumor SUV — 6 Participants

Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…

Primary: [18F] Fluorothymidine ([18F]-FLT) Uptake as a Marker of Cellular Proliferation — 1.57; 3.00 SUV max — p=< 0.001

Primary: Increase of Interferon Gamma Levels — 0 Participants

Primary: Overall Survival — 19 months

Primary: Determine & Comp Biodistribution, Clearance, & Dosimetry of [18F]FACBC & [18F]FLT Tissue/Organs w/i the Field of View of the Dynamic PET Imag Studies prior-to & During…

Primary: Progression-free Survival (PFS) — 91.3 percentage of participants